Provider beliefs associated with cervical cancer screening interval recommendations: A pilot study in Federally Qualified Health Centers  by Roland, Katherine B. et al.
Preventive Medicine Reports 2 (2015) 444–447
Contents lists available at ScienceDirect
Preventive Medicine Reports
j ourna l homepage: ht tp : / /ees .e lsev ie r .com/pmedrProvider beliefs associated with cervical cancer screening interval recommendations:
A pilot study in Federally Qualiﬁed Health Centers☆
Katherine B. Roland a,⁎, April Greek b, Nikki A. Hawkins a, Lavinia Lin a, Vicki B. Benard a
a Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Division of Cancer Prevention and Control,
Epidemiology and Applied Research Branch, Atlanta, GA, USA
b Battelle, Health & Analytics, Seattle, WA, USA☆ Source of funding: Support to A. Greek was provided
and Prevention, contract 200-2002-00573, Task Order No
⁎ Corresponding author at: 4770 Buford Hwy, NE, MS
Fax: +1 770 488 4639.
E-mail address: kroland@cdc.gov (K.B. Roland).
http://dx.doi.org/10.1016/j.pmedr.2015.05.008
2211-3355/Published by Elsevier Inc. This is an open accea b s t r a c ta r t i c l e i n f oAvailable online 23 May 2015Keywords:
Cervical cancer screening
FQHC
Medically underserved
Screening intervals
Provider beliefs
Background. Among providers who serve low-income and uninsured women, resistance to extending the
cervical cancer screening interval following normal Pap and co-test results has been documented. Our objective
was to examine provider characteristics and beliefs associated with guideline-consistent screening interval
recommendations.
Method.We collected cross-sectional survey data between 2009 and 2010 from 82 primary care providers in
six Federally Qualiﬁed Health Centers in Illinois, USA. The relationships between characteristics, beliefs, and
screening interval recommendations (1 year vs. 3 years)were testedwith Pearson chi-square, negative binomial
and ordered logistic regression.
Results. Compared to providers who recommended annual intervals after a normal co-test, providers who
recommended a guideline-consistent (i.e., 3 years) screening interval were signiﬁcantly more likely to report
the goodness, ease, and beneﬁt of their recommendation and perceived encouragement for a 3-year interval
from professional organizations and journals (p b .05). Providers who recommended a 3-year interval were
also less likely to report that longer intervals increase patient risk for cervical cancer (p b .05). Interval recom-
mendations were not associated with provider specialty, gender, or years in practice.
Conclusion. Messages that promote the beneﬁts of longer screening intervals after a normal co-test, the
natural history of human papillomavirus and cervical cancer, and low risk of developing cancer with a longer
intervalmay be useful to promote evidence-based screening in this population of Federally QualiﬁedHealth Cen-
ter providers. Dissemination of targeted messages through professional journals and specialty organizations
should be considered.Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
In the United States, screening for cervical cancer is a standard
component of women's routine preventive healthcare, and has dramat-
ically reduced cervical cancer incidence and mortality over the last six
decades (Habbema et al., 2012). Current guidelines recommend screen-
ing intervals of 3 to 5 years following normal test results, based on the
screening test used. Despite successful integration of cervical cancer
screening into women's routine care, some uninsured and low-income
women are screened less often than recommended and suffer dis-
proportionate cervical cancer morbidity, mortality, and late-stage
diagnosis (Benard et al., 2008; Fedewa et al., 2012; Spence et al., 2007).by Centers for Disease Control
. 0006 to Battelle.
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ss article under the CC BY-NC-ND licConversely, too-frequent cervical cancer screening has also been docu-
mented in both the medically underserved and general population
(Corbelli et al., 2014; King et al., 2014; Perkins et al., 2013; Roland
et al., 2011; Teoh et al., 2015; Verrilli et al., 2014; Yabroff et al., 2009).
Plausible explanations include opportunistic clinical service provision
(Habbema et al., 2012), provider specialty (Corbelli et al., 2014; Yabroff
et al., 2009), practice setting (Yabroff et al., 2009) and size (Perkins
et al., 2013), provider concern for losing the patient to follow-up (King
et al., 2014; Perkins et al., 2013; Verrilli et al., 2014), patient expectations
(King et al., 2014; Perkins et al., 2013; Teoh et al., 2015; Verrilli et al.,
2014), and provider knowledge (Teoh et al., 2015).
In 2009, the Centers for Disease Control and Prevention (CDC)
launched the Cervical Cancer (Cx3) Study to examine both provider
and patient knowledge, attitudes, and beliefs about co-testing
(i.e., simultaneous Pap and human papillomavirus testing) and extend-
ed screening intervals in a medically underserved population (Benard
et al., 2014; Hawkins et al., 2013; Roland et al., 2013). Baseline survey
data collected for the study found that many providers recommendedense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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the time recommending a triennial interval. Providers also reported that
extending the screening interval to three years with a normal co-test
would result in the patent not returning annually for others tests and
losing contact with the medical system (Roland et al., 2013). The
purpose of the current analysis was to examine what provider charac-
teristics and beliefs were associated with their screening interval rec-
ommendations (annual versus triennial interval) using the baseline
survey data.
Method
The Cx3 Study was a pilot study conducted in 15 clinics associated
with six Federally Qualiﬁed Health Centers (FQHCs) in Illinois, USA. In
the United States, FQHCs are funded by the U.S. Department of Health
and Human Services' Health Resources and Services Administration
(HRSA) under Section 330 of the U.S. Public Health Service Act. FQHCs
are safety-net clinics, and are mandated to serve an underserved area
or population, offer a sliding fee scale, and provide preventive primary
care services serve almost 22 million patients annually.
In recent years, HRSA-supported FQHCs have received funding
to expand operations and provide clinical services to a greater num-
ber of medically underserved patients (http://bphc.hrsa.gov/about/
healthcenterfactsheet.pdf). Providers working in FQHCs may face
challenges related to increased patient load, and therefore FQHCs
may experience higher staff turnover. Incentives to improve recruit-
ment and retention of clinicians in underserved areas are being
employed (Abrams et al., 2014).
All providers (physicians, nurse practitioners, certiﬁed nurse mid-
wives, and physician assistants) in the participating clinicswho routine-
ly performed cervical cancer screeningwere eligible to participate (n=
109). Between 2009 and 2010, we sent self-administered, cross-
sectional surveys and a $50 cash incentive to eligible providers with
a stamped, self-addressed envelope for return; 98 providers com-
pleted the survey (89.9% response rate).
The survey collected provider demographic characteristics, practice
characteristics, and screening practices and beliefs. A clinical vignetteTable 1
Demographic characteristics of study providers according to screening interval recommendat
2009–2010.
Samp
descr
Col %
Primary specialty Family medicine 35%
OB–GYN/women's health 56%
Other 9%
Total 100%
Type of provider Physician 67%
NP 21%
Other 12%
Total 100%
Provider is OB/GYN physician Other 55%
OB/GYN MD 45%
Total 100%
Gender Male 26%
Female 74%
Total 100%
Years providing care (mean, sd) 8.9 (
Years providing clinical care, 4 categories 1–4 46%
5–9 22%
10–15 12%
16+ 20%
Total 100%
Signiﬁcance of associations with categorical variables was tested with design-adjusted Pearson
Signiﬁcance of the association with the count variable, number of years providing care, was te
All tests adjusted for the clustered sampling design.
a Co-test (simultaneous Pap and human papillomavirus test).asked the provider when they would next screen a woman aged
35 years with a normal co-test result. Response options were 1 year,
2 years, 3 years, N3 years. For this analysis, we used responses from the
clinical vignette to compare the characteristics and beliefs of providers
who recommended a 1-year interval (n = 57) to those of providers
who recommended a 3-year interval (n = 25) (guideline-consistent at
the time of the survey) as a method for deﬁning guideline compliance
and non-compliance. Signiﬁcance of associations between these two in-
terval recommendations were tested with Pearson chi-square, negative
binomial and ordered logistic regression. All methods adjusted for the
clustered sampling design. Missing data was handled with listwise
deletion. CDC's Institutional Review Board approved the study. Addi-
tional details on study methods are published elsewhere Benard et al.,
2014; Roland et al., 2013.
Results
Providers were primarily female (74%), physicians (67%) or nurse
practitioners (21%), trained in OB/GYN (56%) or family medicine
(35%), with an average of 8.9 years of providing clinical care (n = 82).
Gender, specialty, provider type, and years in practice were not found
to be signiﬁcantly associated with screening interval recommendation
(Table 1).
Providers were asked their beliefs about extending screening inter-
vals for a woman aged ≥30 years with a normal co-test result. Providers
who recommended a 3-year interval after a normal co-test weremore
likely to report that extending routine screening to 3 years would be
good (80%), easy (67%) and beneﬁcial (68%) compared to providers
who recommended annual screening after a normal co-test (p b .05)
(Fig. 1).
Providers were asked to report level of agreement with common
concerns about extending the screening interval after a normal co-
test, including the patient not visiting annually for other screening
tests, increased risk for the patient developing cervical cancer, higher
rates of pre-cancer, or the patient losing contact with the medical sys-
tem. Providers who recommended a 3-year interval were signiﬁcantly
more likely to disagree that an extended interval would put the patientions with the co-test a among 82 providers at Federally Qualiﬁed Health Centers, Illinois,
le
iption
Recommended screening interval for patient
aged 35 years with normal co-test this visit
1 year 3 years p-Value
N Row % N Row % N
29 76% 22 24% 7 0.382
46 63% 29 37% 17
7 86% 6 14% 1
82 70% 57 30% 25
55 71% 39 29% 16 0.442
17 59% 10 41% 7
10 80% 8 20% 2
82 70% 57 30% 25
45 73% 33 27% 12 0.179
37 65% 24 35% 13
82 70% 57 30% 25
21 71% 15 29% 6 0.822
61 69% 42 31% 19
82 70% 57 30% 25
9.9) 9.33 (10.5) 7.8 (8.5) 0.513
38 68% 26 32% 12 0.836
18 61% 11 39% 7
10 80% 8 20% 2
16 75% 12 25% 4
82 70% 57 30% 25
chi-square.
sted with negative binomial regression.
38
80
29
16
33
4
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Good Neither Bad
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28
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p=0.016
n=80
p=0.018
n=80
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Fig. 1. Beliefs about extending cervical cancer screening intervals to 3 years after a normal
co-test,a according to screening interval recommendations, among 82 providers at Feder-
ally Qualiﬁed Health Centers, Illinois, 2009–2010. Signiﬁcance of associations between
these two interval recommendations and beliefs were testedwith ordered logistic regres-
sion and adjusted for clustered sampling design. a Co-test (i.e., simultaneous Pap and
human papillomavirus test).
446 K.B. Roland et al. / Preventive Medicine Reports 2 (2015) 444–447at increased risk for cancer (56%) (p b .05) and would result in higher
rates of pre-cancer (68%) (p = .055) (Table 2).
Providers were asked about their perceived support for extending the
screening interval after a normal co-test from patients, clinic administra-
tion, colleagues, professional specialty organizations, national health
organizations, and professional journals. Providers who recommended a
3-year interval were signiﬁcantlymore likely to perceive support for that
practice from professional specialty organizations and journals (80%)
(p b .05) and national health organizations (76%) (p = .051) (Table 2).
Discussion
Despite guidelines recommending longer intervals between cervical
cancer screenings, women continue to be screened annually. These data
identify speciﬁc beliefs associated with providers guideline-consistent
screening interval recommendations, including beliefs about the
goodness, ease, and beneﬁt of extending screening intervals with a
normal co-test result, and that extending the interval will not put the
patient at increased risk of developing cancer or pre-cancer.
Disseminating the positive beliefs found to be associated with 3-year
intervals through professional specialty organizations and professional
journals could be effective for promoting guideline-consistent
interval recommendations among this population, as was found in
a survey of Indiana primary care providers King et al., 2014. Notably,
nonmodiﬁable provider characteristics such as specialty, age, andgender were not associated with interval recommendations in this
analysis.
Additional methods found to be effective for changing provider's
cervical cancer screening knowledge, behaviors and attitudes include
electronic medical record-based tools (White & Kenton, 2013) provider
assessment and feedback, Sabatino et al., 2012 and academic detailing
(Sheinfeld et al., 2000), patient driven inquiry, andmanagement guide-
lines (King et al., 2014). Interventions andmessages about cervical can-
cer screening should prevent the harms and risks of routine screening,
in addition to the beneﬁts. CDC has produced materials to educate pro-
viders and patients on the appropriate use of the co-test that may be
adapted to reﬂect the needs of the target population and the latest sci-
ence (Benard et al., 2014).
To date, no studies have examined provider and patient acceptance
of co-testingwith longer screening intervals in amedically underserved
population, and therefore these are novel data. Collecting information
on beliefs associatedwith FQHCprovider screening interval recommen-
dations is essential because as the science evolves, so will screening
guidelines and screening modalities, and targeting provider beliefs
and attitudes will be critical to promote uptake of new evidence-
based recommendations. Results from this study will assist CDC in pro-
viding technical assistance to cancer screening programs regarding use
of the co-test. Because of the small convenience sample, these ﬁndings
may not be generalizable to other FQHCs or providers in Illinois. Other
limitations include the data were self-reported, incentives were provid-
ed to complete the survey, and additional details on provider training
and demographics are unknown.
Conclusion
Cervical cancer screening in the United States can be improved by
reducing the frequency of screening intervals for over-screened
women to be consistent with guidelines, and directing realized savings
toward increasing screening among rarely or never-screened women
(Kim et al., 2013). We found that screening interval recommendations
were dictated not by provider demographics but by positive beliefs re-
garding longer screening intervals. While this is not surprising, these
ﬁndings do indicate avenues for dissemination of such beliefs that
could be promoted and disseminated to counter views about the risks
of longer screening intervals. Future research regarding how to commu-
nicate relative risk and harms of over-screening is critical. Provider's
perceived risks such as being held accountable for a missed diagnosis
(Roland et al., 2013), as well as losing the patient to follow-up (Roland
et al., 2013) and her risk of developing cancer are genuine. The lack of
widespread and equitable screening participation, particularly among
under- and over-screened women, is a call to action for public health
programs (Plescia et al., 2012). Reducing unnecessary clinical interven-
tion is essential when community-based primary care settings with ﬁ-
nite resources, such as FQHCs, are expected to provide optimal
preventive care services to an underserved patient population.
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Table 2
Level of agreement with statements about extending the cervical cancer screening interval to 3 years after a normal co-testa, according to screening interval recommendations, among 82
providers at Federally Qualiﬁed Health Centers, Illinois, 2009–2010.
Recommend 1-year
interval (%) (n = 57)
Recommend 3-year
interval (%) (n = 25)
p-Value
Extending the screening interval would… Result in patient not visiting annually for
other screening tests (reverse)
Agree 75 80 0.555
Neither 7 12
Disagree 18 8
Put patient at increased risk for cervical
cancer
Agree 40 12 0.036
Neither 23 32
Disagree 37 56
Result in higher rates of cervical pre-cancer Agree 35 20 0.055
Neither 23 12
Disagree 42 68
Cause patients to lose contact with medical
care system
Agree 68 48 0.088
Neither 9 24
Disagree 23 28
Do the following entities encourage or discourage
you to extend the screening interval?
Patients Discourage 18 40 0.105
Neither 67 48
Encourage 16 12
Colleagues Discourage 28 16 0.165
Neither 47 40
Encourage 25 44
Clinic administration Discourage 21 20 0.126
Neither 65 56
Encourage 14 24
Professional journals Discourage 16 0 0.000
Neither 36 20
Encourage 47 80
Professional specialty organizations Discourage 20 0 0.000
Neither 36 20
Encourage 45 80
National health organizations Discourage 16 0 0.051
Neither 31 24
Encourage 53 76
Signiﬁcance of associations between these two interval recommendations and beliefs was tested with ordered logistic regression and adjusted for clustered sampling design. No missing
data.
a Co-test (simultaneous Pap and human papillomavirus test).
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